Greater central subfield thickness and better visual acuity at baseline are associated with longer time to resolution of diabetic macular edema, shows study.
Even Brief Delays in Intravitreal Injection Can Cause Vision Loss
Patients with diabetic eye disease or vein occlusion lost more vision than patients with age-related macular degeneration when they missed an intravitreal injection during the COVID-19 shutdown.
Influence of Baseline Factors on Time to Resolution of Diabetic Macular Edema Following Anti-VEGF Therapy
Study finds that patients with more severe diabetic retinopathy have faster resolution of diabetic macular edema after anti-VEGF treatment than patients with less severe diabetic retinopathy.
Retinal Leakage Pattern and Vascular Tortuosity May Predict Durability of Anti-VEGF Therapy
Study associates leakage patterns and tortuosity in retinal blood vessels with anti-VEGF therapy interval tolerance in patients with diabetic eye disease or retinal vein occlusion.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Consequences of Lapse in Anti-VEGF Therapy During the COVID-19 Pandemic
A lapse in anti-VEGF therapy can cause an irreversible decrease in visual acuity in neovascular age-related macular degeneration.
Predicting Visual Acuity Response to Anti-VEGF Therapy in Macular Edema Secondary to Retinal Vein Occlusion
Study shows that baseline presence of and changes in DRIL burden during the course of disease in RVO is a useful prognostic indicator for VA and can help guide treatment with anti-VEGF therapy.
Advancing Insights into Diabetic Eye Disease
More information is needed about disease pathogenesis, response to treatment and how we prevent complications. Cole Eye Institute’s Rishi Singh, MD, reviews research underway.
Protocol T Leads to Revised Approach to DME Treatment
The Protocol T study has led to lasting changes in how we manage diabetic macular edema at Cole Eye Institute.